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THE PREVALENCE OF CLINICALdepression and presence ofelevated depressive symptomsare higher among persons with
diabetes compared with the general
population.1,2 These associations may be
related to increased risk of depressive
symptoms in individuals with diabetes,
increased risk of type 2 diabetes in indi-
viduals with depressive symptoms, or
both. Several but not all3 longitudinal
studies have reported that elevated
depressive symptomsareassociatedwith
incident type 2 diabetes.4-12 Several fac-
tors associated with depressive symp-
toms, includingobesity-promotinghealth
behaviors (eg, physical inactivity, hyper-
caloric diets)6-10,12 and activation of the
neuroendocrine13-17 and inflammatory
responses18,19 (resulting in increasedcor-
tisol,catecholamines,andcytokines),can
induce insulin resistance and the devel-
opment of type 2 diabetes.
A diagnosis of diabetes or the bur-
den of dealing with its complications
might might also lead to symptoms of
depression.1 We previously showed an
association between prevalent depres-
sive symptoms and treated type 2 dia-
betes; however, because our analysis
was cross-sectional, we could not de-
termine the temporality of this asso-
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Context Depressive symptoms are associated with development of type 2 diabetes, but
it is unclear whether type 2 diabetes is a risk factor for elevated depressive symptoms.
Objective To examine the bidirectional association between depressive symptoms
and type 2 diabetes.
Design, Setting, and Participants Multi-Ethnic Study of Atherosclerosis, a lon-
gitudinal, ethnically diverse cohort study of US men and women aged 45 to 84 years
enrolled in 2000-2002 and followed up until 2004-2005.
Main Outcome Measures Elevated depressive symptoms defined by Center for Epi-
demiologic Studies Depression Scale (CES-D) score of 16 or higher, use of antidepressant
medications, or both. The CES-D score was also modeled continuously. Participants were
categorized as normal fasting glucose (100 mg/dL ), impaired fasting glucose (100-125
mg/dL),or type2diabetes (126mg/dLor receiving treatment).Analysis1 included5201
participants without type 2 diabetes at baseline and estimated the relative hazard of in-
cidenttype2diabetesover3.2yearsfor thosewithandwithoutdepressivesymptoms.Analy-
sis 2 included 4847 participants without depressive symptoms at baseline and calculated
therelativeoddsofdevelopingdepressivesymptomsover3.1years for thosewithandwith-
out type 2 diabetes.
Results In analysis 1, the incidence rate of type 2 diabetes was 22.0 and 16.6 per
1000 person-years for those with and without elevated depressive symptoms, respec-
tively. The risk of incident type 2 diabetes was 1.10 times higher for each 5-unit in-
crement in CES-D score (95% confidence interval [CI], 1.02-1.19) after adjustment
for demographic factors and body mass index. This association persisted following ad-
justment for metabolic, inflammatory, socioeconomic, or lifestyle factors, although it
was no longer statistically significant following adjustment for the latter (relative haz-
ard, 1.08; 95% CI, 0.99-1.19). In analysis 2, the incidence rates of elevated depres-
sive symptoms per 1000-person years were 36.8 for participants with normal fasting
glucose; 27.9 for impaired fasting glucose; 31.2 for untreated type 2 diabetes, and
61.9 for treated type 2 diabetes. Compared with normal fasting glucose, the demo-
graphic–adjusted odds ratios of developing elevated depressive symptoms were 0.79
(95% CI, 0.63-0.99) for impaired fasting glucose, 0.75 (95% CI, 0.44-1.27) for un-
treated type 2 diabetes, and 1.54 (95% CI, 1.13-2.09) for treated type 2 diabetes.
None of these associations with incident depressive symptoms were materially altered
with adjustment for body mass index, socioeconomic and lifestyle factors, and comor-
bidities. Findings in both analyses were comparable across ethnic groups.
Conclusions A modest association of baseline depressive symptoms with incident
type 2 diabetes existed that was partially explained by lifestyle factors. Impaired fast-
ing glucose and untreated type 2 diabetes were inversely associated with incident de-
pressive symptoms, whereas treated type 2 diabetes showed a positive association with
depressive symptoms. These associations were not substantively affected by adjust-
ment for potential confounding or mediating factors.
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ciation.20 Two prospective studies of
adults have shown that type 2 diabe-
tes is associated with an increased risk
of depressive symptoms21,22; however,
several other studies have shown no as-
sociation.11,12,23-25 Other research sug-
gested that obesity and insulin resis-
tance, precursors to type 2 diabetes, are
associated with a lower risk of devel-
oping depression.26-28
Prior studies examining diabetes as a
predictor of elevated depressive symp-
toms have been limited by being con-
ducted only in elderly individuals21,22,25
or using only self-reported diabe-
tes.21,23,25 Because of contradictory find-
ings thus far, additional population-
based studies that include measurements
of diabetes treatment and the presence
of comorbitidies are needed to investi-
gate whether type 2 diabetes is associ-
ated with the development of elevated
depressive symptoms. In this article, we
used repeated measures of fasting blood
glucose and depressive symptoms col-
lected over time to test whether depres-
sive symptoms predicted incident type
2 diabetes and whether participants with
type 2 diabetes at baseline were more
likely to develop elevated depressive
symptoms over follow-up than partici-
pants without it.
METHODS
Study Population
The Multi-Ethnic Study of Atheroscle-
rosis is a multicenter, longitudinal co-
hort study of the occurrence and cor-
relates of subclinical cardiovascular
disease and its progression.29 Because
an additional objective of the study was
to assess ethnic differences in subclini-
cal disease prevalence, risk of progres-
sion, and rates of clinical cardiovascu-
lar disease, participants were recruited
from 4 prespecified racial/ethnic
groups.29 Between July 2000 and Au-
gust 2002, 6814 men and women aged
45 through 84 years who identified
themselves as white, black, Hispanic,
or Chinese and who were free of self-
reported clinical cardiovascular dis-
ease were recruited from 6 US commu-
nities: Baltimore City and Baltimore
County, Maryland; Chicago, Illinois;
Forsyth County, North Carolina; Los
Angeles County, California; Northern
Manhattan and the Bronx, New York;
and St Paul, Minnesota. Additional de-
tails about the design and objectives of
the study have been previously pub-
lished.29 The first examination took
place between 2000 and 2002. The sec-
ond examination occurred between
2002 and 2004, and the third exami-
nation occurred between 2004 and
2005. Written informed consent was
obtained from participants and the
study was approved by institutional re-
view boards of each institution. Par-
ticipants were notified by letter of all
laboratory results, including glucose
values, with a copy to their physician
if they requested it. Because the Cen-
ter for Epidemiologic Studies Depres-
sion Scale (CES-D) is not designed to
ascertain clinical depression, partici-
pants were not notified about elevated
symptoms.
Assessment of Depressive
Symptoms
Depressive symptoms were assessed at
visits 1 and 3 using the CES-D, a 20-
item questionnaire developed to as-
sess depressive symptoms in commu-
nity populations.30 The CES-D items
represent the major components of de-
pression and include depressed mood,
feelings of worthlessness, feelings of
hopelessness, loss of appetite, poor con-
centration, and sleep disturbance. The
Cronbach  for its reliability ranges be-
tween 0.84 and 0.93.31 Participants were
asked to rate each item on a scale from
0 to 3 based on “how often you have
felt this way during the past week.”
Scores range from 0 to 60, with higher
scores indicating more severe depres-
sive symptoms. We recognize that the
CES-D assesses self-reported depres-
sive symptoms and not clinical depres-
sion. For the purpose of our analyses,
elevated depressive symptoms were de-
fined by a CES-D score of 16 or higher,
consistent with mild to moderate de-
pression or dysthymia,32 self-reported
use of antidepressant medications (tri-
cyclics, nontricyclics, and mono-
amine oxidate inhibitors), or both. Par-
ticipants with a CES-D score of 16 or
higher or who were taking antidepres-
sant medications at visit 3 who did not
meet these criteria at visit 1 were con-
sidered to have incident elevated de-
pressive symptoms, as previously de-
fined by our group.20
The CES-D was administered in En-
glish, Spanish, Cantonese, and Man-
darin. The reliability of the CES-D is
comparable with European American,
African American, Mexican Ameri-
can, and Chinese American groups.33,34
Assessment of Diabetes Status
Impaired fasting glucose and type 2 dia-
betes status were determined at each
visit. Participants were asked to fast for
12 hours and to avoid smoking and
heavy physical activity for 2 hours be-
fore each examination. Fasting blood
samples were drawn by venipuncture
from an antecubital vein into vacuum
tubes between 7:30 AM and 10:30 AM.
Serum samples were frozen and stored
at −70°C. Details of serum sampling
and processing have been described
previously.29
Impaired fasting glucose (100 to 125
mg/dL) and type 2 diabetes (fasting glu-
cose, 126 mg/dL; or use of oral hypo-
glycemic medication, insulin, or both)
were defined according to the 2003
American Diabetes Association crite-
ria.35 Those with diabetes were further
subdivided into participants who were
untreated or treated. Incident diabetes
was defined among participants who did
not have diabetes at baseline but devel-
oped diabetes at subsequent visits. The
date of incident diabetes was estimated
at one-half the interval between the last
known date without diabetes and the ex-
amination at which it was diagnosed.
Covariates
Covariates were assessed at baseline ex-
amination using standard protocols as
previously described.20,29 Sex, age, race/
ethnicity, years of education, cigarette
smoking history, and annual income
were self-reported.Prescriptionandover-
the-counter medications were deter-
mined by transcription of medications
brought into clinic. Weight and height
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were measured using a balance beam
scaleandastadiometer, respectively,with
participants wearing light clothing and
no shoes. Height was recorded to the
nearest 0.5 cm and weight to the near-
est 0.5 lb. Body mass index (BMI) was
calculated as weight in kilograms di-
vided by height in meters squared. All
anthropometric measures were taken in
duplicate and averaged. Blood pressure
and lipid levels were measured and cat-
egorized using standard procedures and
current recommendations.20,36-38
Interleukin 6 (IL-6) and C-reactive
protein (CRP) were measured using
standard techniques previously de-
scribed.20 A spot urine sample was col-
lected from each participant, prefer-
ably in the early morning at the
beginning of the clinic visit. Urinary cre-
atinine and albumin were measured
using previously described techniques.20
Participants’ usual diet was character-
ized using a 120-item food frequency
questionnaire, modified from the vali-
dated Insulin Resistance Atherosclero-
sis Study in which comparable validity
was observed for non-Hispanic white,
African American, and Hispanic partici-
pants.39,40 The dietary assessment was
modified to include foods typically eaten
by Chinese groups. We used total daily
caloric intake as a summary variable of
diet. Physical activity was assessed using
the 28-item Typical Week Physical Ac-
tivity Survey.29,41 We summarized physi-
cal activity as the metabolic equivalent
task of minutes per week spent in mod-
erate to vigorous household, outdoor,
sporting, conditioning, and volunteer
activities.
Analysis
Because the 2 objectives of our study re-
quired different population samples, we
describe the analysis samples and pro-
cedures separately below. However, for
both sets of analyses, we began by com-
paring the distribution of baseline char-
acteristics by depressive symptom sta-
tus (analysis 1) or type 2 diabetes status
(analysis 2) using t tests for continuous
variables and 2 tests for categorical vari-
ables. For the nonnormally distributed
continuous variables, comparisons were
made using the Wilcoxon rank sum test
for the 2-group comparison (analysis 1)
or the Kruskal-Wallis test for the 4-group
comparison (analysis 2). Prior to mod-
eling, we tested for effect modification
by creating interaction terms between
categorically elevated depressive symp-
toms and covariates of interest (ie, age,
sex, race/ethnicity, BMI) or between type
2 diabetes status and covariates of inter-
est. Although there was a suggestion that
the association of depressive symptoms
with incident type 2 diabetes was stron-
ger for whites and Chinese Americans,
the direction of association was similar
for all ethnicities. Because no interac-
tions were found for either analysis,
pooled analyses are presented. Inci-
dence rates for type 2 diabetes were cal-
culated using a Poisson regression per-
son-years approach (analysis 1). The
cumulative incidence of elevated depres-
sive symptoms is presented for analysis
2. A 2-sided P value .05 was used to
determine statistical significance. Statis-
tical analyses were performed using Stata
version 8.2 (Stata Corp, College Sta-
tion, Texas).
Depressive Symptoms
and Incident Diabetes (Analysis 1)
Participants were excluded if they had
prevalent untreated or treated type 2 dia-
betes at the first visit (n=1209); were
missing data on type 2 diabetes status
at any of the 3 visits, or on the CES-D
score at baseline (n=201), or on covar-
iates of interest (n=203), leaving 5201
participants for analysis. Incidence rates
of type 2 diabetes were calculated for
participants with elevated depressive
symptoms or who were taking antide-
pressant medication and compared with
incidence rates among those without el-
evated depressive symptoms. The rela-
tive hazard (RH) of developing type 2
diabetes in participants with elevated de-
pressive symptoms compared with those
without was calculated using Cox pro-
portional hazards regression models. Ad-
ditionally, we modeled CES-D as a con-
tinuous variable and reported the RH per
5-point increase in CES-D score.
Toexploremechanismsexplaining the
relation between elevated depressive
symptoms and type 2 diabetes, we used
the following strategies: model 1 in-
cluded terms for age, race/ethnicity, sex,
and examination site. Model 2 in-
cluded the terms in model 1 plus base-
line BMI. Models 3 through 6 included
the terms in model 2 plus the following
terms: model 3, metabolic variables (lipid
levels, blood pressure, fasting insulin
concentration); model 4, inflammatory
markers (IL-6 and CRP levels); model 5,
socioeconomic variables (educational
achievement, annual household in-
come); and model 6, lifestyle variables
(smoking history, daily caloric intake, al-
cohol use, physical activity level).
Diabetes and Incident Depressive
Symptoms (Analysis 2)
Participants were excluded if they had
prevalent depressive symptoms (CES-
D16, antidepressant medication use,
or both) at baseline (n=1022), if they
were missing data on CES-D score at
baseline and visit 3 or on type 2 diabe-
tes status at baseline (n=908), or on co-
variates of interest (n=37), leaving 4847
who were included in this analysis. The
cumulative incidence of elevated de-
pressive symptoms was calculated for
participants by baseline fasting glu-
cose status. Because incident depres-
sive symptoms were only assessed at 1
follow-up visit, we used logistic regres-
sion to calculate the odds ratio (OR) of
developing elevated depressive symp-
toms in participants with impaired fast-
ing glucose and untreated and treated
type 2 diabetes compared with partici-
pants who had normal fasting glucose
at baseline. We again used a series of
multivariate models to investigate
mechanisms explaining the relation be-
tween type 2 diabetes status and el-
evated depressive symptoms. The base
model was the same as that described
above. Subsequent models included
terms for BMI, socioeconomic status,
lifestyle variables, and markers of dia-
betes severity (dyslipidemia [triglycer-
ides 200 mg/dL, high-density lipo-
protein40 mg/dL, or both], presence
of hypertension [blood pressure
140/90 mm Hg or antihypertensive
medication use], and microalbumin-
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uria [urinary albumin:creatinine ratio
30 mg/g]).42 We selected these fac-
tors a priori because of their previ-
ously reported association with the de-
velopment of depression in individuals
with preexisting type 2 diabetes.
To convert triglycerides to milli-
moles per liter, multiply by 0.0113;
high-density lipoprotein to milli-
moles per liter, multiply by 0.0259; and
glucose to millimoles per liter, multi-
ply by 0.0555.
RESULTS
Depressive Symptoms
and Incident Diabetes
Baseline Characteristics. TABLE 1 sum-
marizes the characteristics of the partici-
pants who did not have prevalent type
2 diabetes by baseline depressive symp-
tom status. Compared with partici-
pants without elevated depressive symp-
toms, those with depressive symptoms
were more likely to be younger, female,
less educated, have a lower annual in-
come, smoke cigarettes, and have higher
caloric intake and were less likely to con-
sume alcohol. Elevated depressive symp-
toms were more common among His-
panic and less common among Chinese
American and African American partici-
pants and varied by site. Participants with
elevated depressive symptoms had lower
systolic blood pressure and higher BMI,
high-density lipoprotein cholesterol,
IL-6, and CRP than those without de-
pressive symptoms.
UnivariateandMultivariateAnalyses.
There were 215 incident cases of type 2
diabetes among individuals without el-
evated depressive symptoms and 60 in-
cident cases among those with elevated
depressive symptoms (Table 1). The
crude incidence of type 2 diabetes over
3.2 years was 22.0 per 1000-person years
for those with elevated depresive symp-
toms and 16.6 per 1000 person-years for
those without elevated depressive symp-
toms (RH, 1.37; 95% confidence inter-
val [CI], 1.02-1.90). There was a signifi-
cant graded association between CES-D
per 5-unit higher score and incident di-
abtes in models adjusted for demo-
graphic characteristics and BMI (RH,
1.12; 95% CI, 1.03-1.21 for model 1; RH,
1.10; 95% CI, 1.02-1.19 for model 2;
TABLE 2). The association persisted fol-
lowing adjustment for metabolic, inflam-
matory, and socioeconomic factors; how-
ever, the association was no longer
statistically significant following adjust-
ment for lifestyle factors, even though the
point estimates were not substantially
changed (RH, 1.08; 95% CI, 0.99-
1.19). We observed similar results when
we categorized participants by depres-
sive symptom status (RH range, 1.42-
1.21 with increasing statistical adjust-
Table 1. Characteristics of 5201 Men and Women Without Prevalent Diabetes by Depressive
Symptom Status in the Multiethnic Study of Atherosclerosis, 2000-2002
CES-D16
(n = 4290)
CES-D16 or
Use of
Antidepressant
Medications
(n = 911)
P
Valuea
Age, mean (SD), y 61.5 (10.1) 59.8 (10.2) .001
Sex, No. (%)
Men 2146 (50.0) 272 (29.9)
.001
Women 2144 (50.0) 639 (70.1)
Ethnicity, No. (%)
White 1813 (42.3) 427 (46.9)
Chinese American 549 (12.8) 64 (7.0)
.001
African American 1115 (25.9) 177 (19.4)
Hispanic 813 (18.9) 243 (26.7)
Educational status, No. (%)
High school 759 (17.7) 163 (17.9)
High school 601 (14) 188 (20.6) .001
College 2930 (68.3) 560 (61.5)
Annual income, No. (%), $
15 000 729 (16.9) 219 (24)
15 000 and 24 000 478 (11.1) 127 (13.9)
24 000 and 34 000 525 (12.2) 116 (12.7)
.001
34 000 and 49 000 681 (15.9) 146 (16)
49 000 and 74 000 754 (17.6) 149 (16.4)
74 000 1123 (26.2) 154 (16.9)
Cigarette smoking status, No. (%)
Never 2198 (51.3) 444 (48.9)
Former 1570 (36.7) 319 (35.1) .004
Current 513 (11.9) 146 (16.1)
Current alcohol drinking, No (%) 2551 (73.1) 508 (68.2) .007
Daily caloric intake, median (IQR), calories/d 1483 (1102-2014) 1571 (1159-2175) .001
Intentional exercise, median (IQR),
MET-min/wkb
945 (210-2130) 630 (0-1837.5) .001
Systolic blood pressure, mean (SD), mm Hg 125.2 (20.8) 122.9 (21) .004
BMI, mean (SD) 27.8 (5.2) 28.4 (5.6) .004
Fasting insulin, median (IQR), mIU/L 5.1 (3.4-7.8) 5.2 (3.4-8.1) .55
Cholesterol, mean (SD), mg/dL
LDL 118.6 (30.7) 116.8 (31.9) .11
HDL 51.4 (14.8) 53.6 (14.8) .001
Triglycerides, median (IQR), mg/dL 108 (76-155) 114 (80-160) .13
IL-6, median (IQR), pg/mL 1.1 (0.7-1.8) 1.3 (0.8-1.9) .001
C-reactive protein, median (IQR), mg/Lb 1.7 (0.8-3.9) 2.2 (0.9-4.7) .001
Incident cases of diabetes, No. 215 60
Person-year 12 968 2729
Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; CES-D,
Center for Epidemiologic Studies Depression Scale; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-
density lipoprotein; MET, metabolic equivalent task.
SI conversion factors: To convert C-reactive protein to nmol/L, multiply by 9.524; HDL and LDL cholesterol to mmol/L,
multiply by 0.0259; insulin to pmol/L, multiply by 6.945; triglycerides to mmol/L, multiply by 0.0113.
aFor categorical covariates, the P value was generated from the 2 test. For continuous covariates, the P value was
generated from the analysis of variance. For the nonnormally distributed variables, the P value was generated from
the Wilcoxon rank sum test.
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ment; Table 2). Associations in the fully
adjusted models were similar to those in
the lifestyle-adjusted model.
Diabetes Status and Incident
Depressive Symptoms
Baseline Characteristics. TABLE 3 sum-
marizes the characteristics of partici-
pants by type 2 diabetes status who did
not have prevalent elevated depressive
symptoms at baseline. Compared with
normal participants, those with im-
paired fasting glucose and type 2 diabe-
tes were more likely to be older, male,
and nonwhite, and less physically ac-
tive and to have higher BMI. Partici-
pants with untreated and treated type 2
diabetes had lower educational attain-
ment and annual income, were more
likely to have microalbuminuria and hy-
pertension, and had lower high-
density lipoprotein cholesterol and
higher triglycerides. Participants with
treated type 2 diabetes were least likely
to consume alcohol and had the lowest
daily caloric intake.
UnivariateandMultivariateAnalyses.
There were 336 incident cases of el-
evated depressive symptoms among in-
dividuals with normal fasting glucose,
112 with impaired fasting glucose, 15
with untreated type 2 diabetes, and 60
with treated type 2 diabetes (Table 3).
The incidence rates of elevated depres-
sive symptoms over 3.1 years were 36.8
for participants with normal fasting glu-
cose, 27.9 for those with impaired fast-
ing glucose, 31.2 for those with un-
treated type 2 diabetes , and 61.9 for
those with treated type 2 diabetes per
1000 person-years. Compared with par-
ticipants with normal fasting glucose,
the odds of developing depressive
symptoms were 20% lower in partici-
pants with impaired fasting glucose and
the point estimates changed little fol-
lowing multivariate adjustment (OR
range, 0.78-0.80 with increasing sta-
tistical adjustment; TABLE 4).
Although individuals with untreated
type 2 diabetes were not at increased risk
of developing elevated depressive symp-
toms, those with treated type 2 diabetes
were at increased risk of developing el-
evated depressive symptoms, which per-
sisted following multivariate adjust-
ment (Table 4). In the fully adjusted
model, treated type 2 diabetes was asso-
ciated with a 52% higher odds of devel-
oping elevated depressive symptoms
(OR, 1.52; 95% CI, 1.09-2.12).
Because antidepressants can be used
to treat other conditions, such as dia-
betic neuropathy, we repeated the analy-
ses defining incident depressive symp-
toms only as CES-D scores of 16 or
higher (n=130) and found similar re-
sults. Compared with participants with
normal glucose tolerance, those with
treated type 2 diabetes had a 64% higher
odds (95% CI, 1.18-2.28) of depressive
symptoms following adjustment for age,
sex, race/ethnicity, and examination site.
The magnitude of association increased
to 86% (95% CI, 1.10-3.10) following ad-
ditional adjustment for BMI, socioeco-
nomic status, lifestyle variables, and
markers of diabetes severity.
COMMENT
These findings suggest that individuals
with elevated depressive symptoms have
a modest increased risk of developing
type 2 diabetes during follow-up, inde-
pendent of sociodemographic, eco-
nomic, and metabolic factors. Al-
though this association was no longer
statistically significant after adjustment
for lifestyle factors, point estimates were
largely unchanged by adjustment, sug-
gesting that the association between de-
pressive symptoms and incident type 2
diabetes is not fully explained by life-
style risk factors. We also found that
among individuals without elevated de-
pressive symptoms at baseline, treated
type 2 diabetes was associated with a sig-
nificantly higher odds of developing de-
pressive symptoms during follow-up, in-
dependent of BMI, socioeconomic status,
and comorbidities.
In contrast with the findings for
treated type 2 diabetes, individuals
with impaired fasting glucose and
those with untreated type 2 diabetes
had reduced risk of incident depres-
sive symptoms, although the associa-
tion with untreated type 2 diabetes
was imprecisely estimated and did not
reach our prespecified level of statisti-
cal significance due to small numbers.
In both analyses, findings were
comparable across race/ethnicity. To
our knowledge, this is the first pop-
ulation-based study to show a bidi-
rectional longitudinal association
between type 2 diabetes and elevated
depressive symptoms within the same
cohort.
Table 2. Relative Hazards of Type 2 Diabetes for Each 5-Point Increase in CES-D Score by
Baseline Depressive Symptoms Status in 5201 Men and Women
Model
Relative Hazard (95% Confidence Interval)
Per 5-Unit Increase
in Continuous Depressive Symptoms
(CES-D) Score
Elevated Depressive Symptoms
Compared With Normal or Low
Depressive Symptomsa
1, Baseb 1.12 (1.03-1.21) 1.42 (1.02-1.95)
2, BMIc 1.10 (1.02-1.19) 1.39 (1.02-1.93)
3, Metabolicd 1.11 (1.03-1.19) 1.39 (1.01-1.91)
4, Inflammatorye 1.10 (1.02-1.19) 1.35 (0.98-1.86)
5, SESf 1.11 (1.02-1.20) 1.39 (1.01-1.92)
6, Lifestyleg 1.08 (0.99-1.19) 1.34 (0.94-1.88)
7, Fully-adjustedh 1.10 (1.02-1.20) 1.21 (0.87-1.67)
Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; CES-D,
Center for Epidemiologic Studies Depression Scale; SES, socioeconomic status.
aElevated depressive symptoms were attributed to those whose CES-D score was 16 or higher, were taking anti-
depressant medication, or both.
bAdjusted for age, sex, race/ethnicity, and examination site.
cAdjusted using model 1 criteria and BMI.
dAdjusted using model 2 criteria and log-transformed triglycerides, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, systolic blood pressure, and log-transformed fasting insulin.
eAdjusted using model 2 criteria and for inflammatory markers IL-6 and C-reactive protein.
fAdjusted using model 2 criteria and SES factors: educational status (categorized as high school, high school, and
high school), annual household income (categorized as $15 000, $15 000-$24 000, $24 000-$34 000,
34 000-$49 000, $49 000-$74 000, and $74 000).
gAdjusted using model 2 criteria and daily caloric intake, smoking status, alcohol use, and physical activity.
hFully adjusted using criteria from all models.
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Depressive Symptoms
and Incident Type 2 Diabetes
Several other population-based stud-
ies report an association between de-
pressive symptoms and incident type
2 diabetes.4-12 Depressive symptoms are
associated with several metabolic and
behavioral risk factors for type 2 dia-
betes. First, depressed individuals are
less likely to comply with dietary and
weight loss recommendations43 and
more likely to be physically inac-
tive,6-10,12 contributing to obesity, a
strong risk factor. Participants in our
study with more depressive symp-
toms had poor health behaviors asso-
ciated with diabetes risk. This corrobo-
rates findings from prior studies
showing that depressed individuals
have higher caloric intake,8,20 are less
physically active,6-10,12 and are more
likely to be smokers.6-9,12 However, ad-
justment for these characteristics in our
analyses resulted in minimal attenua-
tion of the association of depressive
symptoms with incident type 2 diabe-
tes, suggesting that this does not fully
explain the association. Additionally,
depressive symptoms are associated
with activation of the hypothalamic-
pituitary-adrenal and sympathoadre-
nal systems44 and increased inflamma-
tion.18,19,44,45 Inflammatory markers are
known risk factors for type 2 diabe-
tes,46 and we observed higher IL-6 and
CRP levels in depressed persons com-
pared with those without elevated de-
pressive symptoms. However, in our
study, adjustment for markers of in-
Table 3. Characteristics of 4847 Men and Women Without Prevalent Depressive Symptoms by Impaired Fasting Glucose and Type 2 Diabetes
Status, 2000-2002
Fasting Glucose Type 2 Diabetes
P
Valuea
Normal
(n=2868) (59.2%)
Impaired
(n=1357) (28.0%)
Untreated
(n=203) (4.2%)
Treated
(n=417) (8.6%)
Age, mean (SD), y 60.7 (10.1) 63.4 (9.8) 63.7 (9.5) 64.9 (9.4) .001
Sex, No. (%)
Men 1298 (45.3) 803 (59.3) 125 (61.6) 226 (54.5)
.001
Women 1565 (54.7) 552 (40.7) 78 (38.4) 189 (45.5)
Ethnicity, No. (%)
White 1322 (46.2) 468 (34.5) 53 (26.1) 69 (16.6)
Chinese American 331 (11.6) 204 (15.1) 30 (14.8) 59 (14.2)
.001
African American 722 (25.2) 388 (28.6) 71 (34.9) 173 (41.7)
Hispanic 488 (17.1) 295 (21.8) 49 (24.1) 114 (27.5)
Education status, No. (%)
High school 339 (11.8) 225 (16.6) 53 (26.1) 110 (26.5)
High school 461 (16.1) 280 (20.7) 40 (19.7) 79 (19.0) .001
College 2063 (72.1) 850 (62.7) 110 (54.2) 226 (54.5)
Annual income, No. (%), $
15 000 427 (14.9) 267 (19.7) 56 (27.6) 116 (27.9)
15 000-24 000 275 (9.6) 180 (13.3) 26 (12.8) 68 (16.4)
24 000-34 000 334 (11.7) 185 (13.7) 22 (10.8) 70 (16.9)
.001
34 000-49 000 466 (16.3) 209 (15.4) 31 (15.3) 55 (13.3)
49 000-74 000 532 (18.6) 211 (15.6) 31 (15.3) 54 (13.0)
74 000 829 (28.9) 303 (22.4) 37 (18.2) 52 (12.5)
Cigarette smoking status, No. (%)
Never 1495 (52.3) 660 (48.8) 99 (49.0) 212 (51.5)
Former 1008 (35.3) 541 (40.0) 88 (43.6) 150 (36.4) .02
Current 354 (12.4) 151 (11.2) 15 (7.4) 50 (12.4)
Daily caloric intake, median (IQR), calories/d 1469 (1094-1980) 1530 (1140-2108) 1548 (1050-2100) 1342 (972-1866) .001
Intentional exercise, median (IQR), MET-min/wk 990 (300-2220) 840 (52-1935) 735 (0-1890) 698 (0-1680) .001
Current alcohol drinking, No. (%) 1743 (74.5) 776 (69.9) 104 (63.8) 164 (50.8) .001
Microalbuminuria, No. (%) 129 (4.5) 125 (9.3) 39 (19.2) 100 (24.2) .001
Hypertension, No. (%) 1007 (35) 667 (49.2) 113 (55.7) 279 (67.2) .001
BMI, mean (SD) 27.2 (4.9) 29.3 (5.3) 30.1 (5.2) 30.1 (5.7) .001
HDL cholesterol, mean (SD), mg/dL 53.1 (15.4) 48.1 (13.3) 45.4 (11.8) 46.2 (12.5) .001
Triglycerides, mean (SD), mg/dL 104 (72-147) 113 (83-167) 129 (89-203) 126.5 (85-188) .001
Incident cases of elevated depressive symptoms, No. 336 112 15 60
Person-years 9139 4013 481 969
Abbreviations: BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; CES-D, Center for Epidemiologic Studies Depression Scale; HDL,
high-density lipoprotein; IQR, interquartile range; MET, metabolic equivalent task.
SI conversion factors: To convert HDL cholesterol to mmol/L, multiply by 0.0259; triglycerides to mmol/L, multiply by 0.0113.
aFor categorical covariates, the P value was generated from the 2 test. For continuous covariates, the P value was generated from the analysis of variance. For the nonnormally
distributed variables, the P value was generated from the Kruskal-Wallis Test.
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flammation did not substantially alter
or explain our observed association. Fi-
nally, antidepressant medication use
can cause weight gain and obesity,47,48
risk factors for type 2 diabetes. We did
not have enough participants (n=374)
using antidepressants to examine the
association between antidepressant
medication use and incident type 2
diabetes.
Type 2 Diabetes and Incident
Depressive Symptoms
In our previous cross-sectional study,
treated type 2 diabetes, but not im-
paired fasting glucose or untreated type
2 diabetes, was associated with depres-
sive symptoms.20 The finding in our
present analysis that treated type 2 dia-
betes is associated with incident de-
pressive symptoms confirms our ear-
lier cross-sectional observation and
those of 2 prior studies.21,22 However,
although our prior analysis showed no
cross-sectional association between im-
paired fasting glucose and untreated
type 2 diabetes and depressive symp-
toms,20 the present analysis suggests a
lower risk of depressive symptoms in
these individuals. Our findings of an as-
sociation in participants with treated
but not untreated type 2 diabetes sug-
gests that the psychological stress as-
sociated with diabetes management may
lead to elevated depressive symptoms.
In addition, adults with treated type 2
diabetes may have a greater number of
diabetic complications and comorbidi-
ties than those who are untreated and
these complications and comorbidi-
ties may lead to elevated depressive
symptoms. Prior studies have shown
that depressive symptoms were asso-
ciated with nephropathy,49 retinopa-
thy,50,51 neuropathy,52,53 and macrovas-
cular disease.54,55 Some,54,56-61 but not
all,62-66 studies report a positive asso-
ciation between the presence and num-
ber of diabetes complications and de-
pressive symptoms. Miraldi et al22 found
that the association between type 2
diabetes and incident depressive
symptoms was attenuated following
adjustment for comorbidities. In our
study, however, adjustment for comor-
bidities, including dyslipidemia, hy-
pertension, and microalbuminuria,
did not explain the association, al-
though we lacked more specific data
on potentially disabling diabetes com-
plications, such as retinopathy and
neuropathy.
We were surprised to find that im-
paired fasting glucose was associated
with a lower risk of elevated depres-
sive symptoms. This might be due to
the complex relationship between obe-
sity and depressive symptoms, with
cross-sectional studies showing either
an inverse, positive, or lack of associa-
tion between the 2.26 In a large middle-
aged European cohort, Lawlor et al26
showed that obese individuals had a
lower risk of depression over 29 years.
Insulin resistance has also been asso-
ciated with a lower risk of incident de-
pression,27,28 although not in all stud-
ies.6 7 Although this might have
explained our finding of impaired fast-
ing glucose, a prediabetic condition,
being associated with lower risk of de-
pressive symptoms, the BMI was simi-
lar in those with impaired fasting glu-
cose and treated type 2 diabetes, and
point estimates were not changed fol-
lowing adjustment for BMI. Finally,
untreated type 2 diabetes was not as-
sociated with incidence of elevated de-
pressive symptoms, which may be re-
lated to less severe disease or fewer
comorbidities. Participants with un-
treated type 2 diabetes had a slightly
lower prevalence of microalbumin-
uria and hypertension than those with
treated type 2 diabetes. However, ad-
justment for these factors did not sub-
stantially affect the associations of un-
treated and treated type 2 diabetes with
incident depressive symptoms. Fur-
ther studies are needed to confirm that
impaired fasting glucose and un-
treated type 2 diabetes are inversely as-
sociated while treated type 2 diabetes
is positively associated with depres-
sive symptoms and to fully ascertain the
mechanisms underlying these associa-
tions.
Strengths
This study was well suited to investi-
gate the complex association between
depressive symptoms and type 2 dia-
betes because it included repeated
measures of both over time along with
characterization of many diabetes com-
plications. Consequently, we could ex-
amine the 2 temporal hypotheses in the
same cohort while simultaneously in-
vestigating mechanisms that might ex-
plain these associations. Further-
more, participants were selected based
on the absence of coronary heart dis-
ease at baseline, a chronic disease also
known to be associated with develop-
ment of depressive symptoms, which
could confound any associations we
might have observed.
Table 4. Relative Odds of Elevated Depressive Symptoms in 4847 Men and Women by
Glucose Tolerance Category
Model
Normal Fasting
Glucose
Relative Odds (95% Confidence Interval)
Impaired Fasting
Glucose
Untreated
Diabetes
Treated
Diabetes
1, Basea 1 [Reference] 0.79 (0.63-0.99) 0.75 (0.44-1.27) 1.54 (1.13-2.09)
2, BMIb 1 [Reference] 0.80 (0.63-1.01) 0.77 (0.45-1.31) 1.59 (1.17-2.18)
3, SESc 1 [Reference] 0.78 (0.62-0.99) 0.71 (0.41-1.21) 1.47 (1.07-2.01)
4, Lifestyled 1 [Reference] 0.81 (0.63-1.03) 0.77 (0.44-1.37) 1.61 (1.16-2.24)
5, Diabetes severitye 1 [Reference] 0.79 (0.62-0.99) 0.76 (0.45-1.30) 1.56 (1.13-2.15)
6, Fully adjustedf 1 [Reference] 0.80 (0.63-1.02) 0.73 (0.41-1.30) 1.52 (1.09-2.12)
aAdjusted for age, sex, race/ethnicity, examination site.
bAdjusted for model 1 criteria and Body Mass Index (BMI).
cAdjusted for model 2 criteria and socioeconomic status (SES). For definition of variables, see footnote “f” in Table 2.
dAdjusted for model 2 criteria and lifestyle factors (see footnote “g” in Table 2 for a definition).
eAdjusted for Model 2 criteria and markers of diabetes severity (dyslipidemia [triglycerides 200 mg/dL, high-density li-
poprotein cholesterol 40 mg/dL, or both; for conversion factors to SI units see Table 1 footnotes], presence of hyper-
tension [blood pressure 140/90 mm Hg, antihypertensive medication use, or both], and microalbuminuria [urinary albumin:
creatinine ratio 30mg/g]).
fFully adjusted using criteria from all models.
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Limitations
The CES-D was not designed to mea-
sure clinical depression; rather, it is a
self-report of symptoms over the past
week and should not be used to make
a psychiatric diagnosis of depression.
However, CES-D is an efficient and
valid tool for epidemiological stud-
ies68 and is commonly used to assess
mild to moderate depression and dys-
thymia in epidemiological studies con-
ducted in the United States.69 Further-
more, depressive symptoms were only
assessed at 1 follow-up time point over
a relatively short duration. Although
including antidepressant use in the defi-
nition of elevated depressive symp-
toms may have misclassified partici-
pants who were taking antidepressants
for other reasons, results were similar
when CES-D scores alone were used to
define elevated depressive symptoms.
Additionally, a recent study illustrates
the utility of using both markers to de-
fine depression because treated partici-
pants may have normal CES-D scores.70
Although we did not find significant in-
teractions by race/ethnicity or sex, the
study may have lacked power to fully
examine these interactions. However,
the direction of the associations was
similar among all ethnicities for both
analyses. For the analysis of depres-
sive symptoms and incident type 2
diabetes, we had limited data on in-
flammatory markers and no data on
neuroendocrine markers, limiting our
ability to explore these biological hy-
potheses in our analyses. Finally, for the
analysis of treated type 2 diabetes and
incident depressive symptoms, we had
limited data on additional diabetes-
specific comorbidities and their sever-
ity, which impaired our ability to de-
termine whether this explained the
observed association.
CONCLUSION
The biological mechanisms by which
depression and type 2 diabetes are as-
sociated remain unclear. However, the
present study contributes to a grow-
ing body of literature indicating a bi-
directional association between these 2
serious long-term diseases. Future stud-
ies should determine whether inter-
ventions aimed at modifying behav-
ioral factors associated with depressiion
will complement current type 2 diabe-
tes prevention strategies. Finally, these
findings suggest that clinicians should
be aware of increased risk of elevated
depressive symptoms in individuals
with treated type 2 diabetes and con-
sider routine screening for depressive
symptoms among these patients.
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